Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 9:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,208 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo (Cohorts 1 and 2) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.

NCT04801043
View directory record Official record
Conditions
Bacterial Infections
Interventions
XNW4107, Imipenem/Cilastatin, placebo
Drug
Lead sponsor
Evopoint Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine

NCT01995617
View directory record Official record
Conditions
Streptococcus Pneumoniae
Interventions
Placebo, GEN-004 Low Dose, GEN-004 Low Dose + Adjuvant, GEN-004 Mid Dose, GEN-004 Mid Dose + Adjuvant, GEN-004 High Dose, GEN-004 High Dose + Adjuvant
Biological
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 11, 2015 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336 in Healthy, Male Subjects

NCT00808119
View directory record Official record
Conditions
Cocaine Dependence
Interventions
RTI-336 (CTDP 31862)
Drug
Lead sponsor
RTI International
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jul 21, 2009 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia

NCT04155645
View directory record Official record
Conditions
Dyslipidemia
Interventions
AZD8233 subcutaneous injection, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Chula Vista, California • Glendale, California • La Mesa, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 7, 2026, 9:57 PM EDT
Active, not recruiting No phase listed Observational

Attention and Interpretation Modification (AIM) for Fear of Cancer Recurrence: An Intervention Development Study

NCT01517945
View directory record Official record
Conditions
Breast Cancer, Rare Cancer
Interventions
AIM materials and assessments
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Pharmacokinetics of Verinurad and Allopurinol in Asian and Chinese Subjects

NCT03836599
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Verinurad, Allopurinol, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Results available

Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis

NCT03334851
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Interventions
PF-06835375, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
17
States / cities
Anniston, Alabama • Beverly Hills, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 7, 2026, 9:57 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06935357
View directory record Official record
Conditions
Immunoglobulin A Nephropathy (IgAN)
Interventions
Felzartamab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
29
States / cities
Little Rock, Arkansas • Apple Valley, California • Carlsbad, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 7, 2026, 9:57 PM EDT
Recruiting Phase 2 Interventional

Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

NCT07441395
View directory record Official record
Conditions
Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema, Eczema, Atopic
Interventions
Soquelitinib, Placebo
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
South San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DMID 23-0015; Lassa Fever CVD 1000

NCT06546709
View directory record Official record
Conditions
Lassa Fever
Interventions
LASSARAB+ aPHAD-SEat 700rU, HDCV Comparator, Normal Saline Placebo, LASSARAB+ aPHAD-SEat 1400rU
Biological · Other
Lead sponsor
Wilbur Chen, MD, MS
Other
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 7, 2026, 9:57 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease

NCT06734234
View directory record Official record
Conditions
Kidney Disease
Interventions
GSK4771261, Placebo matching GSK4771261
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
25 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 2 Interventional Results available

BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence

NCT03320850
View directory record Official record
Conditions
Urinary Incontinence, Overactive Bladder With Urinary Incontinence
Interventions
OnabotulinumtoxinA and Hydrogel admixture, Placebo and Hydrogel admixture
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
61
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 7, 2026, 9:57 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects

NCT03935568
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PU-AD, Placebo
Drug
Lead sponsor
Samus Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Learn About Study Medicine Called PF-07261271 in Healthy People

NCT05536440
View directory record Official record
Conditions
Healthy
Interventions
PF-07261271, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
4
States / cities
Lake Forest, California • Tustin, California • Eatontown, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate

NCT01950520
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Propranolol, Pindolol, Dantrolene, Magnesium Sulfate, Caffeine, Qsymia, Topiramate, Phentermine, Naltrexone, Mirabegron 50mg, Mirabegron 200mg, Placebo Cohort 1, Placebo Cohort 2, Placebo for Mirabegron
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 35 Years · Male only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers

NCT02413255
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-020, TAK-020 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Genz-682452 in Healthy Volunteers

NCT01710826
View directory record Official record
Conditions
Healthy
Interventions
Genz-682452, Placebo
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2014 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional

To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes

NCT01176097
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
AZD5658, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDP-938 in Healthy Subjects

NCT03384823
View directory record Official record
Conditions
RSV Infection
Interventions
EDP-938, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 7, 2026, 9:57 PM EDT
Terminated Phase 1 Interventional

SP16 as a Therapeutic for COVID-19 Induced ARDS

NCT05135624
View directory record Official record
Conditions
SARS CoV 2 Infection, Pneumonia
Interventions
SP16 (6mg), Placebo, SP16 (12 mg)
Drug · Other
Lead sponsor
Serpin Pharma, LLC
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Optimal Human Dose for GII.2 Norovirus (Snow Mountain) Challenge Studies

NCT02473224
View directory record Official record
Conditions
Gastroenteritis Norovirus
Interventions
Norovirus GII.2 Challenge, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 7, 2018 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 2 Interventional

A Study of RO4917523 in Patients With Treatment Resistant Depression

NCT00809562
View directory record Official record
Conditions
Depression
Interventions
Placebo, RO4917523
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
9
States / cities
Oceanside, California • San Diego, California • New Haven, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants

NCT03943056
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BIIB091, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Oct 7, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy Subjects

NCT00856310
View directory record Official record
Conditions
Healthy
Interventions
REGN475 (SAR164877)
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
21 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Altoona, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2012 · Synced Oct 7, 2026, 9:57 PM EDT